Objective-To determine whether the level of lysophosphatidylcholine (lysoPC) generated by lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with severity of inflammation in human atherosclerotic plaques. Elevated plasma Lp-PLA2 is associated with increased cardiovascular risk. Lp-PLA2 inhibition reduces atherosclerosis. Lp-PLA2 hydrolyzes low-density lipoprotein-oxidized phospholipids generating lysoPCs. According to in vitro studies, lysoPCs are proinflammatory but the association between their generation and plaque inflammation remains unknown. Methods and Results-Inflammatory activity in carotid plaques (162 patients) was determined immunohistochemically and by analyzing cytokines in homogenates (multiplex immunoassay). LysoPCs were quantified using mass spectrometry and Lp-PLA2 and the lysoPC metabolite lysophosphatidic acid (LPA) by ELISA. There was a strong correlation among lysoPC 16:0, 18:0, 18:1, LPA, and Lp-PLA2 in plaques. LysoPC 16:0, 18:0, 18:1, LPA, and Lp-PLA2 correlated with interleukin-1, interleukin-6, monocyte chemoattractant protein-1, macrophage inflammatory protein-1, regulated on activation normal T-cell expressed and secreted, and tumor necrosis factor- in plaques. High lysoPC and Lp-PLA2 correlated with increased plaque macrophages and lipids and with low content of smooth muscle cells, whereas LPA only correlated with plaque macrophages. Lp-PLA2, lysoPC 16:0, 18:0, and 18:1, but not LPA were higher in symptomatic than in asymptomatic plaques. 
A rterial inflammation is the principal driving force responsible for atherosclerotic plaque development and destabilization. There is strong evidence that this inflammation is induced by the retention and oxidation of low-density lipoprotein (LDL) in the subendothelial space. 1, 2 Oxidized LDL is cytotoxic and may induce inflammation by causing arterial cell injury and by recruiting oxidized LDL-specific proinflammatory T cells to the artery wall. 3 It has also been proposed that oxidized LDL may activate inflammation directly through interaction with macrophage Toll-like receptors. 4 An alternative pathway through which oxidized LDL may initiate inflammation is through the release of bioactive metabolites. Oxidized phospholipids in LDL are hydrolyzed by lipoprotein-associated phospholipase A2 (Lp-PLA2) to generate lysophosphatidylcholines (lysoPCs) and oxidized nonesterified fatty acids. 5 LysoPCs have been shown to be a potent chemoattractant for T-cells and monocytes, 6, 7 promote endothelial dysfunction, 8 induce release of arachidonic acid, 9 and induce apoptosis of endothelial and vascular smooth muscle cells. 10, 11 These in vitro observations imply that lysoPCs may contribute to the development of atherosclerotic plaques as well as to plaque vulnerability and rupture. This hypothesis is also supported by studies showing that the Lp-PLA2 and lysoPCs content of human carotid plaques predict future cardiovascular events and that Lp-PLA2 and lysoPC's plaque expression are increased in symptomatic human carotid plaques. [12] [13] [14] Plasma levels of Lp-PLA2 and its activity have also been shown to be independent predictors of cardiovascular risk in several evidence supporting a Key role of lp-PlA2-Generated lysophosphatidylcholine in Human Atherosclerotic Plaque inflammation epidemiological studies. [15] [16] [17] [18] These observations have focused attention on Lp-PLA2 as a possible target for the treatment of atherosclerosis. Darapladib, a reversible oral Lp-PLA2 inhibitor, has recently been shown to reduce the development of atherosclerosis in hypercholesterolemic swine and to halt necrotic core expansion and development of coronary plaques in humans. 19, 20 It seems reasonable to assume that darapladib acts by inhibiting the generation of lysoPCs in atherosclerotic lesions, but the possible associations among Lp-PLA2, lysoPCs, and atherosclerotic plaque inflammation in humans remain to be determined. In the present study, we have analyzed the associations of Lp-PLA2 and lysoPC's levels with the degree of inflammation in 162 human carotid plaques.
Methods

Patients
One hundred sixty-two human carotid plaques were collected at carotid endarterectomies. The indications for surgery were plaques associated with ipsilateral symptoms (transient ischemic attack, stroke, or amaurosis fugax) and stenosis, measured by duplex, >70% (n591) or plaques not associated with symptoms and stenosis >80% (n571). All patients were preoperatively assessed by a neurologist. One day before surgery, a venous blood sample was collected (EDTAplasma) from each patient and stored for further analysis. Informed consent was given by each patient. The study was approved by the local ethical committee. The clinical characteristics of the patients are summarized in Table 1 .
sample Preparation and Histology
After surgical removal, plaques were snap-frozen in liquid nitrogen in the operating room. Fragments of 1 mm, from the most stenotic region, were taken for histology. Transversal sections from the fragment were stained with CD68, Oil Red O, -actin, and Masson.
Plaque homogenates were prepared as previously described. 21 lysoPc, lp-PlA2, lPA, Phosphate, and cytokine Assessment Lp-PLA2 in plaque homogenate and plasma were analyzed using ELISA. Lp-PLA2 in LDL was determined with Western blotting. LysoPC's levels in plaque homogenate and plasma were analyzed using mass spectrometry, 22 and cytokines were analyzed with Luminex technology (Human Cytokine/chemokine immunoassay, Millipore Corporation, MA). Monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor (TNF)-, interleukin (IL)-10, and IL-6 release from cultured human mononuclear leukocytes macrophages and endothelial cells were also assessed by ELISA. Lysophosphatidic acid (LPA) levels in plaque homogenate and plasma as well as plaque levels of phosphate were analyzed using ELISA (Echelon Biosciences Inc, Salt Lake City, UT). A more detailed description of the LPA ELISA is provided in the online-only Data Supplement. All values were normalized to plaque total phosphate.
statistics
Non-normally distributed variables were presented as median and interquartile range (IQR) and normally distributed variables were presented as mean and SD or SEM. Two-group comparisons were performed with Mann-Whitney tests as appropriate. Spearman  was used for correlation analysis. Differences were considered statistically significant at P0.05. Adjustments for multiple comparisons were not performed. More detailed description of methods is available in the online-only Data Supplement.
results
Associations Between lp-PlA2 and lysoPc
There was a strong association between the amounts of lysoPC 16 lysoPc, lPA, lp-PlA2, and Plaque inflammation Plaque levels of lysoPC 16:0, 18:0, 18:1, and LPA demonstrated significant associations with the level of several proinflammatory cytokines and chemokines in the plaque including IL-1, IL-6, MCP-1, macrophage inflammatory protein-1, regulated on activation normal T-cell expressed and secreted, and TNF-, and with the exception of LPA also with the anti-inflammatory cytokine IL-10 ( Table 2 ). In contrast, there were inverse relations between the plaque content of lysoPC 16:0, 18:0, 18:1, LPA, and eotaxin (Table  2) , a chemokine that primarily acts on eosinophils. When comparing lysoPC 16:0, 18:0, and 18:1 levels with the histological characteristics of the plaques, associations were observed with the plaque area stained for neutral lipids and macrophages, whereas inverse correlations were found for smooth muscle cell-stained area (Table 3) . LPA was only Figure 2D ). In accordance with lysoPC 16:0 and 18:0, Lp-PLA2 levels correlated with IL-1, IL-6, IL-10, IL-12 (p40), MCP-1, macrophage inflammatory protein-1, regulated on activation normal T-cell expressed and secreted, TNF-, and inversely with eotaxin (Table 2) . Lp-PLA2 also correlated with the histological staining for neutral lipids and macrophages and inversely with smooth muscle cells (Table 3) , but not with collagen as determined with Masson trichrome. There were no significant correlations between plasma Lp-PLA2 and plaque cytokines (data not shown). Lp-PLA2 activity in plaque extracts was also determined. Although these measurements were more difficult to standardize, Lp-PLA2 activity still demonstrated the expected association with Lp-PLA2 mass (r50.24, P0.005) as well as with IL-6, MCP-1, macrophage inflammatory protein-1, regulated on activation normal T-cell expressed and secreted, and TNF- (Table I in the online-only Data Supplement). The Lp-PLA2 activity was also significantly associated with plaque macrophage and neutral lipids (r50.28, P0.001 and r50.28, P0.001, respectively), but not with immunostaining for smooth muscle cell -actin or collagen as assessed by the Masson trichrome staining.
Association of lp-PlA2 and lysoPcs With cardiovascular risk Factors and Treatment
There was a significant association between plasma levels of LDL and the concentrations of lysoPC 16 
effect of lp-PlA2-Generated lysoPc on release of McP-1
The observations of strong associations between the plaque contents of Lp-PLA2, lysoPCs, and proinflammatory cytokines are indicative of a chain of events in which lysoPCs, generated by action of Lp-PLA2 on oxidized phospholipids in LDL, activate local inflammation. However, they do not exclude the possibility that this inflammation is the result of a direct effect of oxidized LDL on inflammatory cells rather than being attributable to the action of Lp-PLA2 on oxidized LDL. To investigate the relative contribution of lysoPC on generation of the proinflammatory effects of oxidized LDL, we exposed cultured human mononuclear leukocytes to 10 or 100 μg/mL of LDL minimally modified by a preincubation with FeSO 4 (mmLDL) with or without addition of the Lp-PLA2 inhibitor SB-435495 (mmLDL sb ). The presence of Lp-PLA2 in the LDL preparations was demonstrated using Western blotting ( Figure 3A) . Exposure of LDL to FeSO 4 resulted in about doubling of the lysoPC content. Coincubation with SB-435495 inhibited 50% of the increase in lysoPC 16:0 and 18:1 and 25% of the increase in lysoPC 18:0 (Table   II in the online-only Data Supplement). Addition of mmLDL resulted in a >3-fold increase in the release of MCP-1 from the cells ( Figure 3B ). About 40% of this increase was inhibited if the cells were exposed to mmLDL that had been generated in the presence of SB-435495 ( Figure 3B ), whereas addition of SB-435495 after FeSO 4 modification of LDL did not affect mmLDL-induced MCP-1 release (data not shown). Similar observations were made for mmLDL-induced release of IL-6 from cultured endothelial cells ( Figure 3C ), whereas mmLDL did not stimulate the release of MCP-1 from endothelial cells ( Figure 3D ). In accordance with the effect on mononuclear leukocytes, mmLDL stimulated the release of MCP-1 from cultured human macrophages by a mechanism that was inhibited by SB-435495 ( Figure 3E ).
discussion
The present observations provide strong support for the notion that lysoPCs generated through hydrolysis of oxidized phospholipids in LDL by Lp-PLA2 play an important role in human atherosclerotic plaque inflammation. The concentration of lysoPC 16:0, 18:0, and 18:1 present in plaques correlated with the plaque content of Lp-PLA2 and lipids, but only lysoPC 16:0 and 18:0 correlated weakly with Lp-PLA2 levels in plasma. The most likely explanation to this observation is that the majority of the lysoPC 16:0, 18:0, and 18:1 in atherosclerotic lesions is generated locally by the action of Lp-PLA2 on oxidized LDL. Alternatively, the action of Lp-PLA2 on oxidized LDL makes the latter smaller and denser (sdLDL), thereby increasing its affinity for extracellular matrix and 
lysoPc, lp-PlA2, and Plaque inflammation
The concept of an important role of lysoPCs in plaque inflammation is well in line with observations from a number of studies performed on cell culture. LysoPC has been shown to attract monocytes and lymphocytes and to induce chemokine secretion in vitro. 6, 7, [25] [26] [27] MCP-1 is a potent chemokine expressed in atherosclerotic lesions and absence of MCP-1 reduces atherosclerosis in mice. 28, 29 LysoPC has been shown to induce the gene expression of MCP-1 in human microvascular endothelial cells as well as in rat aortic smooth muscle cells. 26, 30 In accordance with these studies, we demonstrate here that 40% of the MCP-1 release from human mononuclear leukocytes caused by exposure to mmLDL can be attributed to products of Lp-PLA2 and that there is a strong correlation between the levels of lysoPC and MCP-1 in atherosclerotic lesions. LysoPC has also been shown to enhance the release of IL-6 from peripheral blood mononuclear cells and human coronary artery smooth muscle cells, 9,25 regulated on activation normal T-cell expressed and secreted from microvascular endothelial cells, 26 and TNF- 27 as well as IL-1 from human monocytes. 31 The present findings of significant associations between lysoPC and these cytokines in atherosclerotic plaques support the in vivo relevance of these in vitro studies. In addition, Shi et al 25 showed that TNF- and IL-1 induced Lp-PLA2 activity, which may result in induction of a vicious cycle of lysoPC generation and inflammation.
We further observed an inverse association among lysoPC 16:0, 18:0, 18:1, LPA, Lp-PLA2, and eotaxin, a chemokine attracting eosinophiles. The role of eotaxin in atherosclerosis and as a possible circulating marker for the disease is controversial. 32, 33 Although eotaxin accumulates in atherosclerotic plaques, it is predominantly located in areas rich in vascular smooth muscle cells, 34 but it is not known if it influences the degree of inflammation in the plaque. The negative correlation found in this study among lysoPC 16:0, 18:0, 18:1, LPA, Lp-PLA2, and eotaxin suggests that eotaxin is downregulated in inflammatory plaques. The anti-inflammatory cytokine IL-10 correlated with lysoPCs and Lp-PLA2. IL-10 is expressed in atherosclerotic plaques and is upregulated through the action of ox-LDL. 35, 36 The correlation among Lp-PLA2, lysoPCs, and IL-10 may reflect that IL-10 often increases in inflammation as a counterbalancing factor.
Lp-PLA2 activity was also determined in plaque extracts. In our hands, this assay was more difficult to standardize than that for Lp-PLA2 protein. Lp-PLA2 activity was significantly but not strongly correlated with Lp-PLA2 protein levels. It also demonstrated significant association with several proinflammatory cytokines in the plaque as well as with plaque macrophages and lipids. However, these associations were generally weaker than those for Lp-PLA2 mass possibly because of the difficulties in standardizing the assay.
lPA and Plaque inflammation
A novel observation from this study is the association between plaque levels of LPA and plaque inflammation. LPA is a phospholipid that is derived from enzymatic cleavage of lysophopholipids such as lysoPC. The biological effect of LPA is mediated through a family of G-protein-coupled LPAreceptors 37 and includes stimulation of endothelial-monocyte adhesion in vitro by inducing the expression of adhesion molecules and chemokines. 38, 39 Zhou and coworkers 40 reported that the endothelial release of the chemokine CXCL1 induced by oxidized LDL is mediated through activation of LPA receptors. Accordingly, it is possible that the association between lysoPC and plaque inflammation described here is the effect of the formation of LPA rather than a direct effect of lysoPC.
lp-PlA2 inhibition as a Therapeutic Approach
The proinflammatory properties of lysoPC together with epidemiological observations of an association between high plasma levels of Lp-PLA2 and increased cardiovascular risk have focused attention on Lp-PLA2 inhibition as a possible novel therapeutic approach. 12, [15] [16] [17] [18] Indeed, selective inhibition of Lp-PLA2 with darapladib has been found to reduce the development of coronary atherosclerosis in hypercholesterolemic swine. 19 Treatment with darapladib also inhibited lesion Lp-PLA2 activity, reduced lesion lysoPC content, and downregulated the expression of proinflammatory genes in coronary arteries in this animal model. Moreover, in a recent study of 330 patients with angiographically documented coronary disease, darapladib treatment was found to halt the progression of plaque necrotic core expansion. 20 Darapladib is currently being studied in 2 large phase III trials: Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial, NCT00799903 (STABILITY), a fully enrolled trial involving 15 828 patients with coronary heart disease 41 and the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 Trial, NCT01000727 (SOLID-TIMI 52), which is estimated to include 11 500 patients with acute coronary syndromes. The observations from the present study of a strong association between plaque levels of lysoPC 16:0, 18:0, 18:1, and inflammatory activity suggest that Lp-PLA2 inhibitors, such as darapladib, act by reducing the generation of lysoPC in lesions. The present study also confirms earlier findings that lysoPC and Lp-PLA2 are significantly higher in symptomatic plaques (eg, plaques that are likely to have recent history of rupture) than in asymptomatic plaques, 14 implicating the generation of lysoPCs in the development of plaque vulnerability. In the present study, we also observed an inverse association between the plaque contents of smooth muscle cells and lysoPCs. High concentrations of lysoPC induce apoptosis in endothelial cells and smooth muscle cells, which is detrimental to the formation of a stabilizing cap. 10, 11 This represents another mechanism through which lysoPCs may cause plaque vulnerability. The amount of apoptosis in human carotid plaques, measured with terminal deoxynucleotidyl transferase (TdT) end labeling, has been shown to correlate with lysoPC in the plaques. 12 
limitations of the study
There are some limitations of the present study that should be considered. First, the strong association between plaque lysoPC's levels and inflammation does not prove a causal relation. It cannot, for example, be excluded that this association is because of the circumstance that both are linked to the presence of oxidized LDL in the lesions and that the inflammation is caused by a direct action of oxidized LDL rather than through the generation of lysoPCs. However, our finding that inhibition of Lp-PLA2 during LDL modification by FeSO 4 removes much of the MCP-1-releasing effect suggests that lysoPC 16:0 is responsible for a considerable part of the proinflammatory properties of oxidized LDL.
In conclusion, the present study provides support for the notion that lysoPC 16:0, 18:0, and 18:1 generated through hydrolysis of oxidized phospholipids in LDL by Lp-PLA2 plays an important role in human atherosclerotic plaque inflammation and strengthens the scientific rationale for inhibiting Lp-PLA2 to prevent development of acute cardiovascular events.
